Study to Evaluate the Safety and Efficacy of PEP005(Ingenol Mebutate) Gel, 0.05%, in Patients With Seborrhoeic Keratosis
Status:
Completed
Trial end date:
2010-12-01
Target enrollment:
Participant gender:
Summary
This study is primarily designed to investigate whether treatment, once daily for up to three
consecutive days, with PEP005 (ingenol mebutate) Gel, 0.05% will be safe and tolerable in
patients with Seborrhoeic Keratosis on non-head locations. The secondary endpoint is to
investigate the efficacy of PEP005 Gel, 0.05% when administered for up to three consecutive
days to Seborrhoeic Keratosis on non-head locations.